Australian Medtech Startup is Using AI to Help Newborns in Intensive Care
6 May 2020 This article has been shared from Hive Life and is written by Stephanie H. Read the full original article here. Umbilical venous catheterisation is an emergency procedure performed on premature and critically ill newborns who…
Read MoreNew Report: COVID-19’s impact on the medical research institute workforce could be severe
11 May 2020 A new report titled “Impact of the Pandemic on Australia’s Research Workforce”, compiled by sector lead organisations with the Chief Scientist – has painted a troubling extended outlook for the research community. “As the report…
Read MoreJoint industry statement: Industry unites in call to back our biotechs to keep jobs during COVID-19
11 May 2020 Despite this being the life sciences industry’s ‘finest hour’ as it pivots to fast track COVID-19 vaccines, treatment and diagnostics and digital health solutions, the sector’s pre-revenues companies are calling for support to keep their…
Read MoreCE mark for Trajan’s hemaPEN® blood microsampling device, now available for diagnostic use across EU and UK
7 May 2020 Trajan Scientific and Medical (Trajan) has declared hemaPEN® compliance with EU IVD Directive 98/79/EC, and its release for in vitro diagnostic use in the EU and UK. This follows the hemaPEN’s recent addition to the…
Read MoreCertara & DMTC Collaborate to Study Using Chloroquine in Healthcare Workers at Risk for COVID-19
7 May 2020 Certara®, the global leader in model-informed drug development, and DMTC (formerly the Defence Materials Technology Centre) Ltd, which works to enhance Australia’s defense and medical countermeasure capabilities, have entered into a…
Read MoreCynata Receives Ethics Approval to Commence Clinical Trial in COVID-19 and Clinical Development Update
8 May 2020 Cynata Therapeutics Limited, a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that it has received ethics committee approval to commence a clinical trial to investigate early efficacy of Cynata’s proprietary CymerusTM…
Read MoreFlorey researchers to pursue first-in-clinic treatment for severe infant epilepsy
8 May 2020 Researchers at the Florey, in collaboration with the University of Melbourne, will pursue a potentially life-changing precision medicine treatment for children with severe forms of epilepsy, thanks to a new multi-year grant awarded from the…
Read MoreAdAlta update: Dr Tim Oldham interviewed by Pitt Street Research
8 May, 2020 Our CEO, Dr Tim Oldham recently sat down with Stuart Roberts of Pitt Street research to talk about AdAlta’s growth strategy and upcoming Phase 1 clinical trials of lead candidate, AD-214. In the interview, Dr…
Read MoreKilling ‘sleeper cells’ may enhance breast cancer therapy
7 May 2020 The anti-cancer medicine venetoclax could improve the current therapy for estrogen receptor-positive (ER+) breast cancer – the most common form of breast cancer in Australia – according to preclinical studies led by Walter and Eliza…
Read MoreTessara Therapeutics Raises $2.7 Million to Develop Mimetic Brain Tissue
7 May 2020 · Tessara™ Therapeutics Pty Ltd closed their Round 1 capital raise with $2.7M invested, significantly over-subscribed by Australian and New Zealand-based sophisticated investors. · A New South Wales-based syndicate, including medical specialists and a neurosurgeon,…
Read MoreSienna enters New Zealand market with its hTERT IVD
6 May 2020 Sienna Cancer Diagnostics Ltd (ASX:SDX) (“Sienna” or “the Company”) is pleased to announce the appointment of Scientle Innovations (“Scientle”) as its exclusive distributor in New Zealand. The distribution agreement provides Scientle with the right to…
Read MoreCSL Behring Australia Commences Development of Treatment for Serious Cases of COVID-19
6 May 2020 CSL Behring Australia, a subsidiary of CSL Limited, today announced that it will begin immediate onshore development of an anti-SARS-CoV-2 plasma product with the potential to treat people with serious complications of COVID-19, particularly those…
Read More
